Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Meteoroid

In this page

Clinical Trial

NCT05271409 Recruiting, Active
Meteoroid

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab As Monotherapy Or In Addition To Baseline Therapy In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Phase 3
Interventional

Disease

Disease type

MOGAD

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

30/08/2022

Closing date

31/07/2026

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Pr Paul Friedemann

Representative

Germany

Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8)
See more

Pr Philipp Albrecht

Representative

Germany

See more

Pr Carlo Traverso

Representative

Italy

See more

ERN EYE member investigating site

HCP : Principal investigators